Where do CRISPR Therapeutics's ratios come from?

Every ratio is computed from CRISPR Therapeutics's SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.

	FY'25	FY'24	FY'23	FY'22
Profitability
Operating margin	-18,933.6%-17,683pp	-1,250.4%—	——	-56,190.4%—
Net margin	-16,569.8%-15,588pp	-981.5%—	——	-54,271.7%—
Returns
Return on equity	-30.2%-11.0pp	-19.2%—	——	-30.4%—
Return on invested capital	-36.5%-10.5pp	-26%—	——	-37.3%—
Efficiency
Asset turnover	0×0.0×	0×-0.1×	0.2×+0.2×	0×-0.4×
Liquidity
Current ratio	13.3×-8.8×	22.1×+4.5×	17.5×+2.2×	15.3×-4.9×
Leverage
Debt-to-equity	0.1×0.0×	0.1×0.0×	0.1×0.0×	0.1×0.0×
Per Share
Book value per share	$21.37-6.7%	$22.90-3.6%	$23.77-1.5%	$24.12-19.2%
Valuation
Market capitalization	$5B+48.8%	$3.36B-32.4%	$4.97B+56.2%	$3.18B-45.1%
Price / sales	1,423.8×+1,334×	90×+76.6×	13.4×-2,643×	2,656.6×+2,650×
Price / book	2.6×+0.9×	1.7×-0.9×	2.6×+0.9×	1.7×-0.7×

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Ask your AI about CRISPR Therapeutics.

Connect your AI assistant and get a quick read on the numbers, right in your chat.

Connect your AI

Claude

Questions, answered.

Where do CRISPR Therapeutics's ratios come from?: Every ratio is computed from CRISPR Therapeutics's SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.